Alcentra Capital (ABDC) Is At $6.71 Formed Wedge; Eulav Asset Management Has Increased Its Biogen (BIIB) Stake

Biogen Inc. (NASDAQ:BIIB) Logo

Alcentra Capital Corporation (ABDC) formed wedge down with $6.44 target or 4.00% below today’s $6.71 share price. Alcentra Capital Corporation (ABDC) has $92.28 million valuation. The stock decreased 1.47% or $0.1 during the last trading session, reaching $6.71. About 43,192 shares traded. Alcentra Capital Corporation (NASDAQ:ABDC) has declined 49.03% since May 18, 2017 and is downtrending. It has underperformed by 60.58% the S&P500.

Eulav Asset Management increased Biogen Inc (BIIB) stake by 23.81% reported in 2017Q4 SEC filing. Eulav Asset Management acquired 7,500 shares as Biogen Inc (BIIB)’s stock declined 17.01%. The Eulav Asset Management holds 39,000 shares with $12.42M value, up from 31,500 last quarter. Biogen Inc now has $59.20B valuation. The stock decreased 0.33% or $0.94 during the last trading session, reaching $280.57. About 1.16 million shares traded. Biogen Inc. (NASDAQ:BIIB) has declined 3.66% since May 18, 2017 and is downtrending. It has underperformed by 15.21% the S&P500.

Since January 9, 2018, it had 1 buy, and 5 selling transactions for $10.09 million activity. The insider PANGIA ROBERT W sold $1.92M. Sandrock Alfred sold 908 shares worth $266,444. 48,000 shares valued at $12.96M were bought by DENNER ALEXANDER J on Wednesday, April 25.

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Fool.com which released: “Better Buy: Amgen Inc. vs. Biogen Inc.” on May 15, 2018, also Bizjournals.com with their article: “Biogen, Shire called out by FDA for ‘gaming’ generic access rule” published on May 17, 2018, Seekingalpha.com published: “Biogen Q1 2018: Too Cheap To Ignore” on April 25, 2018. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Seekingalpha.com and their article: “Biogen: Down Too Far, Too Fast?” published on April 25, 2018 as well as Seekingalpha.com‘s news article titled: “Biogen Buy Signal: Alzheimer’s Royalties Option” with publication date: May 02, 2018.

Investors sentiment increased to 1.17 in 2017 Q4. Its up 0.04, from 1.13 in 2017Q3. It improved, as 46 investors sold BIIB shares while 305 reduced holdings. 105 funds opened positions while 305 raised stakes. 180.65 million shares or 0.28% less from 181.16 million shares in 2017Q3 were reported. First Republic Inv Incorporated invested in 43,142 shares. Dimensional Fund Advsrs Limited Partnership holds 565,696 shares or 0.07% of its portfolio. Suntrust Banks Incorporated reported 0.03% in Biogen Inc. (NASDAQ:BIIB). 925 are owned by Edgemoor Inv. Guggenheim Cap Lc, a Illinois-based fund reported 281,505 shares. Wealthtrust stated it has 0% in Biogen Inc. (NASDAQ:BIIB). 8,724 are held by Stevens Capital Mgmt Limited Partnership. Bnp Paribas Asset Mgmt Hldgs accumulated 90,396 shares or 0.25% of the stock. Asset Management Gp reported 0.07% in Biogen Inc. (NASDAQ:BIIB). Nomura has 25,842 shares. Comerica Securities reported 1,140 shares. Quantbot Technology Ltd Partnership, New York-based fund reported 322 shares. Waverton owns 290,016 shares or 5.4% of their US portfolio. Tiaa Cref Investment Mgmt Ltd Liability Corporation reported 0.29% of its portfolio in Biogen Inc. (NASDAQ:BIIB). 14,867 were reported by Kepos L P.

Eulav Asset Management decreased Disney Walt Co (NYSE:DIS) stake by 30,000 shares to 34,000 valued at $3.66M in 2017Q4. It also reduced Wright Med Group N V stake by 23,000 shares and now owns 30,200 shares. Dexcom Inc (NASDAQ:DXCM) was reduced too.

Among 33 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 24 have Buy rating, 0 Sell and 9 Hold. Therefore 73% are positive. Biogen Idec Inc. had 132 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, October 24 by Cowen & Co. As per Thursday, November 5, the company rating was upgraded by Piper Jaffray. The rating was downgraded by Citigroup on Tuesday, June 7 to “Neutral”. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Tuesday, November 8 by Mizuho. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Outperform” rating by Bernstein on Monday, July 27. The stock has “Hold” rating by BMO Capital Markets on Friday, October 20. The company was maintained on Thursday, October 22 by H.C. Wainwright. The firm has “Buy” rating by Piper Jaffray given on Thursday, January 18. The stock of Biogen Inc. (NASDAQ:BIIB) has “Hold” rating given on Tuesday, July 25 by Stifel Nicolaus. The company was upgraded on Wednesday, April 25 by Robert W. Baird.

Analysts await Alcentra Capital Corporation (NASDAQ:ABDC) to report earnings on August, 2. They expect $0.20 earnings per share, down 44.44% or $0.16 from last year’s $0.36 per share. ABDC’s profit will be $2.75 million for 8.39 P/E if the $0.20 EPS becomes a reality. After $0.27 actual earnings per share reported by Alcentra Capital Corporation for the previous quarter, Wall Street now forecasts -25.93% negative EPS growth.

Among 7 analysts covering Alcentra Capital Corp (NASDAQ:ABDC), 2 have Buy rating, 0 Sell and 5 Hold. Therefore 29% are positive. Alcentra Capital Corp had 16 analyst reports since August 12, 2015 according to SRatingsIntel. Robert W. Baird downgraded the shares of ABDC in report on Monday, November 7 to “Neutral” rating. The rating was downgraded by Oppenheimer on Monday, November 7 to “Perform”. Keefe Bruyette & Woods maintained Alcentra Capital Corporation (NASDAQ:ABDC) on Sunday, August 6 with “Hold” rating. The firm has “Hold” rating by Keefe Bruyette & Woods given on Sunday, October 22. Keefe Bruyette & Woods maintained it with “Hold” rating and $7.0 target in Thursday, March 15 report. The stock has “Hold” rating by Raymond James on Thursday, January 11. Janney Capital initiated the stock with “Neutral” rating in Wednesday, June 22 report. On Thursday, August 13 the stock rating was maintained by Oppenheimer with “Outperform”. The firm has “Hold” rating given on Wednesday, May 31 by Keefe Bruyette & Woods. The stock has “Hold” rating by Oppenheimer on Friday, August 4.

Alcentra Capital Corporation (NASDAQ:ABDC) Ratings Chart